A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Autor: Nicola D. Kerrison, Carlos González, Mark Walker, Adam S. Butterworth, Martina Müller-Nurasyid, Mark I. McCarthy, Jarmo Virtamo, Nilesh J. Samani, Daniel F. Freitag, Jennifer Wessel, Inês Barroso, Jette Bork-Jensen, Marit E. Jørgensen, Torben Hansen, Nita G. Forouhi, Jennifer A. Smith, Peter Vollenweider, Douglas F. Easton, Heiner Boeing, Helena M. Earl, Laufey T. Amundadottir, Annette Peters, Ingrid B. Borecki, L. Adrienne Cupples, Li Li, Josée Dupuis, Sara Benlloch Garcia, J. Wouter Jukema, Shuai Wang, Veikko Salomaa, Jukka Kontto, Timothy J. Key, Yuning Chen, Sune F. Nielsen, Robin Young, Jing Hua Zhao, Andrew P. Morris, Larraitz Arriola, Claudia Langenberg, Joshua C. Bis, Nisa M. Maruthur, Ele Ferrannini, Joanna M. M. Howson, Marcel den Hoed, Jeanette Erdmann, Rosalind A. Eeles, Daphne L. van der A, Panos Deloukas, Eric Boerwinkle, Sara M. Willems, Elio Riboli, Markku Laakso, Gina M. Peloso, Muriel J. Caslake, Nadia Slimani, Zsofia Kote-Jarai, Paul W. Franks, EPIC-InterAct, Dominique Arveiler, Sarah Bowden, Janet A. Dunn, Jan-Håkan Jansson, Carlos Cruchaga, Audrey Y. Chu, James S. Pankow, Rudolf Kaaks, Jerome I. Rotter, Jaspal S. Kooner, Ailith Pirie, Johanna Kuusisto, Hanieh Yaghootkar, Niels Grarup, Danish Saleheen, Thomas Foltynie, Jean Abraham, Stefan Blankenberg, Mark O. Goodarzi, Markus Perola, Olov Rolandsson, Chris J. Packard, Praveen Surendran, Allan Linneberg, Beverley Balkau, Christopher J. Poole, Frank Kee, Carmen Navarro, Nicholas J. Wareham, Oluf Pedersen, Heribert Schunkert, Domenico Palli, Patricia B. Munroe, Sven J. van der Lee, Chunyu Liu, Rebecca Sims, Georg Ehret, Michael Boehnke, Stephen J. Sharp, Peter M. Nilsson, Salvatore Panico, Børge G. Nordestgaard, Aldi T. Kraja, Sara Grioni, Sekar Kathiresan, Dawn M. Waterworth, Francesco Gianfagna, Jacek Czajkowski, Naveed Sattar, Margaret G. Ehm, Christopher J. Gillson, Karen L. Mohlke, Stella Trompet, John Danesh, Carlotta Sacerdote, Gaëlle Marenne, Jian'an Luan, Timothy M. Frayling, J. Ramón Quirós, Iciar Aviles-Olmos, Robert A. Scott, Yvonne T. van der Schouw, Jennifer L. Aponte, María José Sánchez, Deborah J. Thompson, Klaudia Walter, James B. Meigs, Tibor V. Varga, Kari Kuulasmaa, Torben Jørgensen, Rosario Tumino, Kyriaki Michailidou, Kenneth Muir, Philippe Amouyel, Ian Ford, Aurelio Barricarte, Stephen O'Rahilly, Ali Amin Al Olama, Louise Hiller, Alena Stančáková, Carlos Caldas, Jean Ferrières

Publikováno v: 341ra76
Scott, R A, Freitag, D F, Li, L, Chu, A Y, Surendran, P, Young, R, Grarup, N, Stancáková, A, Chen, Y, Varga, T V, Yaghootkar, H, Luan, J, Zhao, J H, Willems, S M, Wessel, J, Wang, S, Maruthur, N, Michailidou, K, Pirie, A, van der Lee, S J, Gillson, C, Al Olama, A A, Amouyel, P, Arriola, L, Arveiler, D, Aviles-Olmos, I, Balkau, B, Barricarte, A, Barroso, I, Garcia, S B, Bis, J C, Blankenberg, S, Boehnke, M, Boeing, H, Boerwinkle, E, Borecki, I B, Bork-Jensen, J, Bowden, S, Caldas, C, Caslake, M, Cupples, L A, Cruchaga, C, Czajkowski, J, den Hoed, M, Dunn, J A, Earl, H M, Ehret, G B, Ferrannini, E, Ferrieres, J, Jørgensen, T & CVD50 consortium 2016, ' A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease ', Science Translational Medicine, vol. 8, no. 341, 341ra76 . https://doi.org/10.1126/scitranslmed.aad3744
Scott, R A, Freitag, D F, Li, L, Chu, A Y, Surendran, P, Young, C R, Grarup, N, Stancakova, A, Chen, Y, Varga, T V, Yaghootkar, H, Luan, J, Zhao, J H, Willems, S M, Wessel, J, Wang, S, Maruthur, N M, Michailidou, K, Pirie, A, Van Der Lee, S J, Gillson, C J, Amin Al Olama, A, Amouyel, P, Arriola, L, Arveiler, D, Aviles-Olmos, I, Balkau, B, Barricarte, A, Barroso, I, Garcia, S B, Bis, J C, Blankenberg, S, Boehnke, M, Boeing, H, Boerwinkle, E, Borecki, I B, Bork-Jensen, J, Bowden, S, Caldas, C, Caslake, M, Cupples, L A, Cruchaga, C, Czajkowski, J, den Hoed, M, Dunn, J A, Earl, H M, Ehret, G B, Ferrannini, E, Ferrieres, J, Foltynie, T, Ford, I, Forouhi, N G, Gianfagna, F, Gonzalez, C A, Grioni, S, Hiller, L, Jansson, J H, Jørgensen, M E, Jukema, J W, Kaaks, R, Kee, F, Kerrison, N D, J. Key, T, Kontto, J, Kote-Jarai, Z, Kraja, A T, Kuulasmaa, K, Kuusisto, J, Linneberg, A, Liu, C, Marenne, G, Mohlke, K L, Morris, A P, Muir, K, Müller-Nurasyid, M, Munroe, P B, Navarro, C, Nielsen, S F, Nilsson, P M, Nordestgaard, B G, Packard, C J, Palli, D, Panico, S, Peloso, G M, Perola, M, Peters, A, Poole, C J, Quiros, J R, Rolandsson, O, Sacerdote, C, Salomaa, V, Sánchez, M-J, Sattar, N, Sharp, S J, Sims, R, Slimani, N, Smith, J A, Thompson, J D, Trompet, S, Tumino, R, van der A, D L, van der Schouw, Y T, Virtamo, J, Walker, M, Walter, K, Abraham, J E, Amundadottir, L T, Butterworth, A S, Aponte, J L, Dupuis, J, Easton, D F, Eeles, R A, Erdmann, J, Franks, P W, Frayling, T M, Hansen, T, Howson, J M M, Jørgensen, T, Kooner, J, Laakso, M, McCarthy, M I, Pankow, J S, Pedersen, O, Riboli, E, Rotter, J I, Saleheen, D, Samani, N J, Schunkert, H, Vollenweider, P, O'Rahilly, S, Deloukas, P, Danesh, J, Goodarzi, M O, Kathiresan, S, Meigs, J B, Ehm, M G, Wareham, N J & Waterworth, D M 2016, ' A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease ', Science Translational Medicine, bind 8, nr. 341 . https://doi.org/10.1126/scitranslmed.aad3744
SCIENCE TRANSLATIONAL MEDICINE
Scott, R A, Freitag, D F, Li, L, Chu, A Y, Surendran, P, Young, R, Grarup, N, Stancáková, A, Chen, Y, Varga, T V, Yaghootkar, H, Luan, J, Zhao, J H, Willems, S M, Wessel, J, Wang, S, Maruthur, N, Michailidou, K, Pirie, A, van der Lee, S J, Gillson, C, Al Olama, A A, Amouyel, P, Arriola, L, Arveiler, D, Aviles-Olmos, I, Balkau, B, Barricarte, A, Barroso, I, Garcia, S B, Bis, J C, Blankenberg, S, Boehnke, M, Boeing, H, Boerwinkle, E, Borecki, I B, Bork-Jensen, J, Bowden, S, Caldas, C, Caslake, M, Cupples, L A, Cruchaga, C, Czajkowski, J, den Hoed, M, Dunn, J A, Earl, H M, Ehret, G B, Ferrannini, E & Ferrieres, J & Foltynie, T 2016, ' A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease ', Science Translational Medicine, vol. 8, no. 341, pp. 341ra76 . https://doi.org/10.1126/scitranslmed.aad3744
Science Translational Medicine, 8(341)
Science Translational Medicine, 8(341):341ra76. American Association for the Advancement of Science
Science Translational Medicine, Vol. 8, No 341 (2016) P. 341ra76
Science Translational Medicine, 8(341). American Association for the Advancement of Science

Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2df1af35c1e4c46ac1448dacdbce98
http://hdl.handle.net/11588/650489

Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy

Autor: Darragh Duffy, Eric G. Meissner, Henry Masur, Shyam Kottilil, Matthew L. Albert, Jérémie Decalf, Armanda Casrouge

Publikováno v: PLoS ONE
PLoS ONE, 2015, 10 (7), pp.e0133236. ⟨10.1371/journal.pone.0133236⟩
PLoS ONE, Vol 10, Iss 7, p e0133236 (2015)
PLoS ONE, Public Library of Science, 2015, 10 (7), pp.e0133236. ⟨10.1371/journal.pone.0133236⟩

Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negativ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34288c84d102b5e0fb82496371553986
https://hal-pasteur.archives-ouvertes.fr/pasteur-01380964/file/journal.pone.0133236.PDF

Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence

Autor: Massimo Locati, Elena Monica Borroni, Raffaella Bonecchi, Paul Proost, Alberto Mantovani, Benedetta Savino, Nina Machado Torres, Sofie Struyf, Anneleen Mortier

The chemokine decoy receptor D6 controls inflammatory responses by selective recognition and degradation of most CCR1 to CCR5 agonistic ligands. CCL14 is a homeostatic chemokine present at high concentrations in the serum with a weak agonist activity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654dfb1c35edc3f328766f781dd42a7b
https://doi.org/10.1074/jbc.m109.029249